Nasal Spray Costs Are Disclosed By Bharat Biotech In A Dispute With Covid
The COVID-19 intranasal vaccine iNCOVACC, which is now offered on the CoWIN site, is priced at 800 (excluding GST) for private markets and 325 (excluding GST) for government supplies, according to Bharat Biotech International Limited on December 27.
The vaccine is scheduled to be administered in the fourth week of January 2023, according to a press release from the manufacturer.
The first intranasal COVID vaccination in the world to be approved for both a heterologous booster dose and the primary two-dose regimen is iNCOVACC.
The Central Drugs Standard Control Organization (CDSCO) gave Bharat Biotech permission to employ heterologous booster dosages of iNCOVACC earlier this month.
According to the press announcement, phase-III trials of iNCOVACC (as a two-dose regimen) were carried out for safety and immunogenicity in almost 3100 people across 14 trial sites in India, while heterologous booster dosage studies were carried out in 875 subjects for safety and immunogenicity.
It was noted that iNCOVACC was created in collaboration with Washington University in St. Louis, which had created the recombinant adenoviral vector construct and assessed its efficiency in pre-clinical investigations.
News Mania Desk
